Serotonin releasing agent

Effects and comparisons

Selectivities and serotonin increases

A number of somewhat selective SRAs have been well-studied, for instance fenfluramine and meta-chlorophenylpiperazine (mCPP). Although fenfluramine and mCPP are efficacious SRAs, they are also highly potent agonists of serotonin 5-HT2 receptors, including of the serotonin 5-HT2A, 5-HT2B, and particularly 5-HT2C receptors. Direct activation of serotonin receptors such as the serotonin 5-HT2C receptor with fenfluramine has been shown to be therapeutically relevant in humans, as dexfenfluramine produces appetite suppressant effects even when its serotonin release is blocked by concomitant treatment with the selective serotonin reuptake inhibitor (SSRI) fluoxetine. Similarly, mCPP is an extremely potent agonist of the serotonin 5-HT2C receptor and produces robust effects thought to be 5-HT2C receptor-mediated in in animals and humans, such as anxiety and panic. In addition to serotonin receptor agonism, fenfluramine is also a norepinephrine releasing agent with several-fold lower potency compared to serotonin release. As such, the serotonin 5-HT2 receptor agonism and other actions of these agents may modify their effects, and a fully selective SRA could produce very different effects.

The 2-aminoindane MMAI, and certain cathinones, have increased selectivity for serotonin release compaired to fenfluramine and mCPP. Chlorphentermine is also notable in being a highly selective SRA, including having negligible activity as an agonist of all three of the serotonin 5-HT2 receptors. 4-Methylthioamphetamine (4-MTA) was originally described as a selective SRA, but was subsequently found to efficiently induce dopamine release as well, and is also known to act as a potent monoamine oxidase A (MAO-A) inhibitor. MMA has been found to act as a highly selective SRA, but has also been reported to produce psychedelic-like effects in both animals and humans.

SRAs achieve far greater increases in serotonin levels than SRIs and have substantially more robust of effects, both in animals and in terms of subjective effects in humans. Whereas the SSRI fluoxetine can increase serotonin levels in the hypothalamus in rats by up to 4-fold, the SRA dexfenfluramine can increase serotonin levels as much as 9- to 16-fold or more. Relatedly, genetic ablation of the serotonin transporter (SERT), which results in complete loss of SERT-mediated serotonin reuptake, is associated with 4- to 6-fold elevations in brain serotonin levels. SRIs produce subtle interoceptive cues that are difficult for animals to recognize in drug discrimination testing, whereas SRAs produce robust cues that are easily recognized and learned.

Stimulant-like and rewarding effects

Certain SRAs, such as fenfluramine and chlorphentermine, do not produce locomotor activation (a stimulant-like effect) in animals. Moreover, fenfluramine robustly inhibits the locomotor hyperactivity and rewarding effects induced by psychostimulants like amphetamine and phentermine. Whereas amphetamine and phentermine produce strong locomotor stimulation in rodents, combination of fenfluramine and phentermine results in only weak locomotor activation and substantial reduction in conditioned place preference (CPP). Fenfluramine also suppresses the subjective effects and positive mood effects of amphetamine and phentermine in humans.

In spite of the preceding however, it has also been reported that the SRA dexfenfluramine weakly but dose-dependently stimulates locomotor activity in rodents. Combination of dexfenfluramine with the selective serotonin 5-HT2C receptor antagonist SB-242084 results in dexfenfluramine dramatically and dose-dependently enhancing locomotion. However, it has also been reported that serotonin 5-HT2B and 5-HT2C receptor antagonism with SB-206553 does not allow fenfluramine to produce robust hyperactivity, although further addition of amphetamine does produce marked hyperlocomotion (greater than with amphetamine alone). The reasons for these conflicting findings are unclear. In any case, in other research, serotonin 5-HT2B receptor knockout or selective serotonin 5-HT2B receptor antagonism with RS-127445 has been found to abolish MDMA-induced serotonin release and locomotor hyperactivity. As with reported findings with fenfluramine, whereas the SRA and serotonin 5-HT2C receptor agonist mCPP decreases locomotor activity normally, it increases locomotor activity in serotonin 5-HT2C receptor knockout mice or with serotonin 5-HT2C receptor antagonism. This increased locomotor activity could be blocked by a serotonin 5-HT1B receptor antagonist. However, other research suggests that the serotonin 5-HT2A receptor is also involved in mCPP-induced hyperlocomotion in the context of serotonin 5-HT2C receptor inactivation.

In contrast to fenfluramine and mCPP, the SSRI fluoxetine has no impact on locomotor activity alone or in combination with SB-242084. In addition to its modulation of locomotion, the suppressive effects of fenfluramine on drug self-administration are blocked by SB-242084.

Whereas certain SRAs like fenfluramine and chlorphentermine do not increase locomotor activity, other SRAs, including MDMA, MDEA, MBDB, para-chloroamphetamine (PCA), (S)-MDA, α-methyltryptamine (αMT), and α-ethyltryptamine (αET), are able to dose-dependently increase locomotor activity. Moreover, this effect appears to be serotonin-dependent, as it can be blocked by pretreatment with SSRIs like fluoxetine (which prevent the serotonin-releasing effects of SRAs). Similarly, the non-selective serotonin receptor antagonist methysergide as well as the serotonin synthesis inhibitor para-chlorophenylalanine (PCPA) block the hyperlocomotion of αMT. Contrasting with the preceding findings, the suppression of locomotor activity by fenfluramine and its metabolite dexnorfenfluramine is not blocked by fluoxetine, indicating that it is not due to induction of serotonin release. Similarly, MMAI dose-dependently suppresses locomotor activity, and this is likewise not blocked by fluoxetine nor by the non-selective serotonin receptor antagonist metitepine. However, it was, contrarily, antagonized by the serotonin synthesis inhibitor PCPA. MDAI suppresses locomotor activity initially, but there is rebound locomotor stimulation at a high dose, and this was described as similar to the profile of MDMA. The increased locomotion induced by SRAs that cause this effect appears to be critically dependent on serotonin 5-HT1B receptor signaling. Conversely, 5-HT2C receptor antagonists markedly enhance the hyperlocomotion of MDMA.

In terms of reinforcing properties, MDMA produces dose-dependent CPP, MDAI produces CPP, MBDB produces weak CPP, fenfluramine produces conditioned place aversion (CPA), and MMAI has no effect on place conditioning at lower doses but produces CPA similarly to fenfluramine at high doses. mCPP had no effect on place conditioning, at least in one study. SSRIs have shown highly mixed effects on place conditioning, with fluoxetine producing CPP, zimelidine producing CPP or having no effect, and citalopram producing CPA. Though zimelidine was reported to produce CPP in one study, it could also block the CPP induced by amphetamine.

Effects on intracranial self-stimulation (ICSS) can be used to measure the reinforcing and misuse-related effects of drugs. ICSS is enhanced by amphetamine and is reduced by the serotonin 5-HT2C receptor agonist Ro 60-0175, by the SRA and serotonin 5-HT2C receptor agonist fenfluramine, and by the κ-opioid receptor agonist U-69,593 in rats. The serotonin–norepinephrine–dopamine releasing agents (SNDRAs) and serotonin receptor agonists (+)-MDMA and naphthylaminopropane (NAP; PAL-287) showed mixed effects on ICSS, either augmenting or suppressing ICSS depending on the ICSS frequencies. The serotonin 5-HT2C receptor antagonist SB-242084 completely blocked the suppressive effects of Ro 60-0175 and fenfluramine on ICSS, whereas it did not influence the effects of amphetamine or U-69,593 on ICSS. SB-242084 partially reduced the ICSS suppressive effects of (+)-MDMA and NAP and augmented their facilitatory effects on ICSS. Conversely, the non-selective serotonin receptor antagonist methysergide completely blocked the ICSS depression produced by MDMA. These findings suggest that serotonin 5-HT2C receptor activation plays a major role in the anti-reinforcing effects of SRAs, but that other serotonin receptors may also be involved.

Psychedelic-like effects

Fenfluramine dose-dependently induces the head-twitch response, a behavioral proxy of psychedelic-like effects, and this is assumed to be due to activation of serotonin 5-HT2A receptors. Conversely, fluoxetine does not produce head twitches at any dose. In accordance with animal findings, very high doses of fenfluramine have been reported to produce LSD-like psychedelic effects in humans. The psychedelic effects of fenfluramine may be mediated by direct serotonin 5-HT2A receptor agonism, as other SRAs like MDMA, PCA, and chlorphentermine have been reported not to produce the head-twitch response in animals and PCA has not been reported to produce hallucinogenic effects in humans. In contrast to fenfluramine, PCA is notably not a serotonin 5-HT2A receptor agonist or may only act as one at high doses, chlorphentermine shows very weak or negligible activity at the serotonin 5-HT2 receptors, and MDMA is a relatively low-potency and low-efficacy partial agonist of the serotonin 5-HT2A receptor. In conflict with the preceding findings however, PCA has been reported to robustly induce the head-twitch response in animals in other studies, and this appeared to be dependent on induction of serotonin release as opposed to direct serotonin 5-HT2A receptor agonism, since it could be largely blocked by an SRI or by serotonin synthesis inhibitor. In any case, SRAs are described as not inherently hallucinogenic in humans, and hence the induction of the head-twitch response with them has been considered a false-positive for psychedelic effects.

Antidepressant-like effects

SSRIs like fluoxetine, as well as non-selective SRIs, are used and claimed to be clinically effective in the treatment of depression. SRAs produce far more robust of increases in serotonin levels than SRIs. On the basis of these findings, it has been proposed that SSRAs may be more effective antidepressants than SSRIs and may have a faster onset of action. Accordingly, SSRAs like MMAI and 4-MTA, as well as non-selective SRAs like fenfluramine, show antidepressant-like effects in animal tests, for instance in the chronic mild stress (CMS) test and the forced swim test (FST), and show greater magnitudes of effects than SSRIs ike sertraline.

In addition to its antidepressant-like effects, MMAI has shown anxiolytic-like effects in animals. Relatedly, SRAs have been suggested for potential treatment of anxiety disorder, panic disorder, obsessive–compulsive disorder (OCD), and other conditions as well.

Although SRAs might be more effective than SRIs for uses like depression treatment, SRAs may also have greater risks than SRIs, for instance higher risk of serotonin syndrome. Tachyphylaxis to their beneficial therapeutic effects might also occur.

A few SRAs have in fact already been clinically studied and/or marketed as antidepressants in the past. These include αET, which was previously marketed in the United States under the brand name Monase; α-methyltryptamine (αMT), which was previously marketed in the Soviet Union under the brand name Indopan; fenfluramine, which has been clinically studied for depression but was never approved for this use; and PCA, which has been clinically studied for depression but was discontinued due to animal findings of serotonergic neurotoxicity.

Examples and use of SRAs

Fenfluramine, chlorphentermine, and aminorex, which are also amphetamines and relatives, were formerly used as appetite suppressants but were discontinued due to concerns of cardiac valvulopathy. This side effect has been attributed to their serotonin release and/or the additional action of potent agonism of the 5-HT2B receptor in the case of fenfluramine. Indeloxazine is said to be an SRA and norepinephrine reuptake inhibitor (NRI) that was formerly used as an antidepressant, nootropic, and neuroprotective.

Amphetamines like MDMA, MDEA, MDA, and MBDB, among other relatives (see MDxx), are recreational drugs termed entactogens. They act as serotonin–norepinephrine–dopamine releasing agents (SNDRAs) and also agonize serotonin receptors, such as those in the 5-HT2 subfamily.

Some tryptamines, such as DMT, bufotenin, and psilocin, are SRAs as well as non-selective serotonin receptor agonists. Psilocin is a partial releaser of serotonin, with an of 54%. These drugs are serotonergic psychedelics, which is a consequence of their ability to activate the 5-HT2A receptor. Other tryptamines, including tryptamine itself, αET, and αMT, are SNDRAs and non-selective serotonin receptor agonists. αET and αMT were originally thought to act as monoamine oxidase inhibitors (MAOIs) and were formerly used as antidepressants, but are now encountered solely as recreational drugs. αET and αMT are described as being entactogen-like.

Mechanism of action

Main article: Monoamine releasing agent#Mechanism of action

List of SRAs

Pharmaceutical drugs and related

Amphetamines

Main article: Substituted amphetamine

• Amiflamine (FLA-336) (also an MAOI)
• Chlorphentermine (Apsedon, Desopimon, Lucofen)
• Cloforex (Oberex) (prodrug of chlorphentermine)
• Dexfenfluramine (Redux) (enantiomer of fenfluramine)
• Etolorex (prodrug of chlorphentermine; never marketed)
• Fenfluramine (Pondimin, Fen-Phen)
• Flucetorex (related to chlorphentermine; never marketed)
• Levofenfluramine (enantiomer of fenfluramine)
• Norfenfluramine (metabolite of fenfluramine)

Tryptamines

Main article: Substituted tryptamine, Substituted α-alkyltryptamine

• α-Ethyltryptamine (αET, AET; etryptamine; Monase; withdrawn)
• α-Methyltryptamine (αMT, AMT; Indopan; withdrawn)

Others

• Carbamazepine (Equetro, Epitol, and many other variations)
• Indeloxazine (Elen, Noin) (non-selective; discontinued)
• Viqualine (PK-5078) (also a GABAA receptor ; never marketed)

Recreational drugs and research chemicals

Amphetamines

Main article: Substituted amphetamine

• 3-Methoxy-4-methylamphetamine (MMA)
• 4-Methoxyamphetamine (PMA)
• 4-Methoxy-N-ethylamphetamine (PMEA)
• 4-Methoxy-N-methylamphetamine (PMMA)
• 4-Methylthioamphetamine (4-MTA)

Ring-extended amphetamines

• 2-Methyl-3,4-methylenedioxyamphetamine (2-Methyl-MDA)
• 3-Methyl-4,5-methylenedioxyamphetamine (5-Methyl-MDA)
• 3,4-Ethylenedioxy-N-methylamphetamine (EDMA)
• 3,4-Methylenedioxyamphetamine (MDA)
• 3,4-Methylenedioxyethylamphetamine (MDEA)
• 3,4-Methylenedioxymethamphetamine (MDMA)
• 5-(2-Aminopropyl)benzofuran (5-APB)
• 5-(2-Aminopropyl)-2,3-dihydrobenzofuran (5-APDB)
• 5-Indanyl-2-aminopropane (IAP)
• 5-MABB
• 5-MAPB
• 6-(2-Aminopropyl)benzofuran (6-APB)
• 6-MABB
• 6-MAPB
• 6-Tetralinyl-2-aminopropane (TAP)
• N-Methyl-1,3-benzodioxolylbutanamine (MBDB)
• Methamnetamine (MNAP; PAL-1046)
• Naphthylaminopropane (NAP; PAL-287)
• ODMA
• SeDMA
• TDMA

Cathinones

Main article: Substituted cathinone

• Butylone (βk-MBDB)
• Mephedrone (4-methylmethcathinone; 4-MMC)
• Methylone (3,4-methylenedioxymethcathinone; MDMC)

Phenyloxazolamines

Main article: Substituted phenyloxazolamine

• Aminorex
• 3',4'-Methylenedioxy-4-methylaminorex (MDMAR)

2-Aminoindanes

Main article: Substituted 2-aminoindane

• 5-Methoxy-2-aminoindane (MEAI, 5-MeO-AI)
• 5-Methoxy-6-methylaminoindane (MMAI)
• 5,6-Methylenedioxy-N-methyl-2-aminoindane (MDMAI)
• 5,6-Methylenedioxy-2-aminoindane (MDAI)
• 5-Trifluoromethyl-2-aminoindane (TAI)
• N-Ethyl-5-trifluoromethyl-2-aminoindane (ETAI)

1-Aminomethylindanes

Main article: Substituted 1-aminomethylindane

• 1-Aminomethyl-5-methoxyindane (AMMI)

2-Aminotetralins

Main article: Substituted 2-aminotetralin

• 6-Chloro-2-aminotetralin (6-CAT)
• 6,7-Methylenedioxy-2-aminotetralin (MDAT)
• 6,7-Methylenedioxy-N-methyl-2-aminotetralin (MDMAT)

Phenylpiperazines

Main article: Substituted phenylpiperazine

• meta-Chlorophenylpiperazine (mCPP)
• 3-Trifluoromethylphenylpiperazine (TFMPP)

Tryptamines

Main article: Substituted tryptamine, Substituted α-alkyltryptamine

• 5-Chloro-αET
• 5-Chloro-αMT
• 5-Fluoro-αET
• 5-Fluoro-αMT
• βk-NM-αMT
• Dimethyltryptamine (DMT)
• Methylethyltryptamine (MET)
• Psilocin
• Bufotenin
• Tryptamine

Isotryptamines

Main article: Substituted isotryptamine

• α-Methylisotryptamine (isoAMT)

References

References

1. (April 2002). "Serotonin releasing agents. Neurochemical, therapeutic and adverse effects". Pharmacol Biochem Behav.
2. (August 2024). "Direct serotonin release in humans shapes aversive learning and inhibition". Nat Commun.
3. (1993). "Novel serotonergic agents". Drug des Discov.
4. (2000). "Neurochemical mechanisms of phentermine and fenfluramine: Therapeutic and adverse effects". Drug Development Research.
5. (August 2003). "Discriminative stimulus effects of m-chlorophenylpiperazine as a model of the role of serotonin receptors in anxiety". Life Sci.
6. (February 2009). "Current status of inverse agonism at serotonin2A (5-HT2A) and 5-HT2C receptors". Pharmacol Ther.
7. (May 2003). "The pre-clinical behavioural pharmacology of 3,4-methylenedioxymethamphetamine (MDMA)". Neurosci Biobehav Rev.
8. (October 2003). "Monoamine transporters and psychostimulant drugs". Eur J Pharmacol.
9. (March 2019). "2-Aminoindan and its ring-substituted derivatives interact with plasma membrane monoamine transporters and α2-adrenergic receptors". Psychopharmacology (Berl).
10. (June 1994). "Behavioral effects of the highly selective serotonin releasing agent 5-methoxy-6-methyl-2-aminoindan". Eur J Pharmacol.
11. (July 1998). "Drug discrimination studies of the interoceptive cues produced by selective serotonin uptake inhibitors and selective serotonin releasing agents". Psychopharmacology (Berl).
12. (February 2023). "Serotonin-releasing agents with reduced off-target effects". Mol Psychiatry.
13. (December 1992). "p-methylthioamphetamine is a potent new non-neurotoxic serotonin-releasing agent". Eur J Pharmacol.
14. (December 2012). "4-Methylthioamphetamine increases dopamine in the rat striatum and has rewarding effects in vivo". Basic Clin Pharmacol Toxicol.
15. (2019). "Amphetamine Derivatives as Monoamine Oxidase Inhibitors". Front Pharmacol.
16. (May 1991). "Synthesis and pharmacological examination of 1-(3-methoxy-4-methylphenyl)-2-aminopropane and 5-methoxy-6-methyl-2-aminoindan: similarities to 3,4-(methylenedioxy)methamphetamine (MDMA)". Journal of Medicinal Chemistry.
17. (October 2024). "Chemistry/structural biology of psychedelic drugs and their receptor(s)". Br J Pharmacol.
18. (1991). "Pihkal: A Chemical Love Story". Transform Press.
19. (2006). "Therapeutic potential of monoamine transporter substrates". Curr Top Med Chem.
20. (July 2015). "Therapeutic Potential of 5-HT2C Receptor Agonists for Addictive Disorders". ACS Chem Neurosci.
21. (July 1999). "Effects of 5-HT-releasing agents on the extracellullar hippocampal 5-HT of rats. Implications for the development of novel antidepressants with a short onset of action". Neuropharmacology.
22. (December 1997). "The Effect of Selective Serotonin Releasing Agents in the Chronic Mild Stress Model of Depression in Rats". Stress.
23. (December 2005). "Targeted screening for biogenic amine transporters: potential applications for natural products". Life Sci.
24. (September 2016). "Decreased Incentive Motivation Following Knockout or Acute Blockade of the Serotonin Transporter: Role of the 5-HT2C Receptor". Neuropsychopharmacology.
25. (December 2006). "Dual dopamine-5-HT releasers: potential treatment agents for cocaine addiction". Trends Pharmacol Sci.
26. (August 2006). "Balance between dopamine and serotonin release modulates behavioral effects of amphetamine-type drugs". Ann N Y Acad Sci.
27. (January 2007). "Dual dopamine/serotonin releasers as potential medications for stimulant and alcohol addictions". AAPS J.
28. (December 2008). "Dual dopamine/serotonin releasers: potential treatment agents for stimulant addiction". Exp Clin Psychopharmacol.
29. (April 1996). "Evaluation of phentermine and fenfluramine, alone and in combination, in normal, healthy volunteers". Neuropsychopharmacology.
30. (1 January 2002). "Behavioral Psychopharmacology of MDMA and MDMA-Like Drugs: A Review of Human and Animal Studies". Informa UK Limited.
31. (August 2010). "Mice in ecstasy: advanced animal models in the study of MDMA". Curr Pharm Biotechnol.
32. (March 2008). "Serotonin 5-HT2B receptors are required for 3,4-methylenedioxymethamphetamine-induced hyperlocomotion and 5-HT release in vivo and in vitro". J Neurosci.
33. (July 2002). "Therapeutic and adverse actions of serotonin transporter substrates". Pharmacol Ther.
34. (April 2004). "mCPP-induced hyperactivity in 5-HT2C receptor mutant mice is mediated by activation of multiple 5-HT receptor subtypes". Neuropharmacology.
35. (1996). "Serotonergic functions in arousal and motor activity". Behav Brain Res.
36. (1991). "Amphetamine derivatives induce locomotor hyperactivity by acting as indirect serotonin agonists". Psychopharmacology (Berl).
37. (1993). "Suppression of behavioral activity by norfenfluramine and related drugs in rats is not mediated by serotonin release". Psychopharmacology (Berl).
38. (1994). "Synthesis of trans-2-(indol-3-yl)cyclopropylamines: Rigid tryptamine analogues".
39. (2017). "Synthetic Aminoindanes: A Summary of Existing Knowledge". Front Psychiatry.
40. (June 2001). "3,4-Methylenedioxymethamphetamine (MDMA) as a unique model of serotonin receptor function and serotonin-dopamine interactions". J Pharmacol Exp Ther.
41. (August 2008). "Locomotor stimulation produced by 3,4-methylenedioxymethamphetamine (MDMA) is correlated with dialysate levels of serotonin and dopamine in rat brain". Pharmacol Biochem Behav.
42. (January 2002). "Pharmacological studies of the acute effects of (+)-3,4-methylenedioxymethamphetamine on locomotor activity: role of 5-HT(1B/1D) and 5-HT(2) receptors". Neuropsychopharmacology.
43. (December 1998). "Measuring reward with the conditioned place preference paradigm: a comprehensive review of drug effects, recent progress and new issues". Prog Neurobiol.
44. (September 2021). "Serotonergic regulation of the dopaminergic system: Implications for reward-related functions". Neurosci Biobehav Rev.
45. (January 1996). "Reinforcing effects of certain serotonin-releasing amphetamine derivatives". Pharmacol Biochem Behav.
46. (September 2016). "Locomotor, discriminative stimulus, and place conditioning effects of MDAI in rodents". Behav Pharmacol.
47. (April 1993). "Conditioned place aversion induced by 5-HT(1C) receptor antagonists". Behav Pharmacol.
48. (June 1986). "Different effects of zimelidine on the reinforcing properties of d-amphetamine and morphine on conditioned place preference in rats". Eur J Pharmacol.
49. (April 2016). "Neurochemical substrates of the rewarding effects of MDMA: implications for the development of pharmacotherapies to MDMA dependence". Behav Pharmacol.
50. Bauer, Clayton. (2013). "Determinants of Abuse-Related Effects of Monoamine Releasers in Rats". VCU Libraries.
51. (September 2015). "Role of 5-HT₂C receptors in effects of monoamine releasers on intracranial self-stimulation in rats". Psychopharmacology (Berl).
52. (January 1997). "Serotonergic modulation of 3,4-methylenedioxymethamphetamine (MDMA)-elicited reduction of response rate but not rewarding threshold in accumbal self-stimulation". Brain Res.
53. (January 2017). "The serotonin 5-HT2C receptor and the non-addictive nature of classic hallucinogens". J Psychopharmacol.
54. Gunne LM. (1977). "Drug Addiction II: Amphetamine, Psychotogen, and Marihuana Dependence". Springer.
55. Connell, P. H.. (1979). "Drug dependence liability of anorectic drugs: a clinical viewpoint, with particular reference to fenfluramine". Current Medical Research and Opinion.
56. Griffith, John D.. (1977). "Cocaine and Other Stimulants". Springer US.
57. (November 1975). "A comparison of fenfluramine and amphetamine in man". Clin Pharmacol Ther.
58. (March 2023). "Experimental strategies to discover and develop the next generation of psychedelics and entactogens as medicines". Neuropharmacology.
59. (February 2023). "Psychedelics promote neuroplasticity through the activation of intracellular 5-HT2A receptors". Science.
60. (October 1977). "Substituted amphetamine derivatives. II. Behavioural effects in mice related to monoaminergic neurones". Acta Pharmacol Toxicol (Copenh).
61. (October 2018). "Dark Classics in Chemical Neuroscience: 3,4-Methylenedioxymethamphetamine". ACS Chem Neurosci.
62. (March 2014). "Behavioral and neurochemical pharmacology of six psychoactive substituted phenethylamines: mouse locomotion, rat drug discrimination and in vitro receptor and transporter binding and function". Psychopharmacology (Berl).
63. (2018). "Behavioral Neurobiology of Psychedelic Drugs". Springer Berlin Heidelberg.
64. (May 2020). "Correlation between the potency of hallucinogens in the mouse head-twitch response assay and their behavioral and subjective effects in other species". Neuropharmacology.
65. (May 1992). "Effects of p-chloroamphetamine on brain serotonin neurons". Neurochem Res.
66. (1988). "Effects of 5,7-dihydroxytryptamine and 6-hydroxydopamine on head-twitch response induced by serotonin, p-chloroamphetamine, and tryptamine in mice". Psychopharmacology (Berl).
67. (December 2023). "Molecular and Medical Aspects of Psychedelics". Int J Mol Sci.
68. (1998). "The serotonin transporter: a primary target for antidepressant drugs". J Psychopharmacol.
69. (February 1978). "Behavioural despair in rats: a new model sensitive to antidepressant treatments". Eur J Pharmacol.
70. (December 2023). "α-Ethyltryptamine: A Ratiocinatory Review of a Forgotten Antidepressant". ACS Pharmacol Transl Sci.
71. (20 March 2012). "Medical Toxicology of Drug Abuse: Synthesized Chemicals and Psychoactive Plants". John Wiley & Sons.
72. Shulgin, Alexander T.. (1978). "Stimulants". Springer US.
73. (July 2018). "Identification and characterization of 4-chloromethamphetamine (4-CMA) in seized ecstacy - a risk to public health". Forensic Sci Int.
74. (1971). "A comparative study of the therapeutic effects of sone 4-chlorinated amphetamine derivatives in depressive patients". Psychopharmacologia.
75. (October 2014). "Interaction of psychoactive tryptamines with biogenic amine transporters and serotonin receptor subtypes". Psychopharmacology.
76. (April 2012). "Studies of the biogenic amine transporters. 14. Identification of low-efficacy "partial" substrates for the biogenic amine transporters". The Journal of Pharmacology and Experimental Therapeutics.
77. (October 1998). "Carbamazepine-induced release of serotonin from rat hippocampus in vitro". Epilepsia.
78. (June 1997). "Carbamazepine increases extracellular serotonin concentration: lack of antagonism by tetrodotoxin or zero Ca2+". European Journal of Pharmacology.
79. (June 2001). "Pharmacological discrimination between effects of carbamazepine on hippocampal basal, Ca(2+)- and K(+)-evoked serotonin release". British Journal of Pharmacology.
80. (September 1998). "Neurochemical and behavioral characterization of potential antidepressant properties of indeloxazine hydrochloride". Neuropharmacology.